Last reviewed · How we verify

NCT04277286: EVATRANSEND

Evaluation of the TRANSEND Program

Completed Last updated 2 March 2022
What this trial tests

trial testing survey in Pediatric Patient Transfer to Adult Service:Transition Program in 202 participants. Completed in 10 October 2020.

Timeline
9 September 2020
Primary endpoint
10 October 2020
10 October 2020

Quick facts

Lead sponsorAssistance Publique - Hôpitaux de Paris
StatusCompleted
Study typeOBSERVATIONAL
Enrollment202
Start date9 September 2020
Primary completion10 October 2020
Estimated completion10 October 2020
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Adults 18 to 32, any sex, with Pediatric Patient Transfer to Adult Service:Transition Program. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

"Transend" is a program designed to promote the transition of young patients with endocrine or metabolic diseases when they arrive in the adult sector at La Pitié-Salpétrière hospital. The main objective of the study is to compare the rate of patients lost to follow-up at 24 months after the transfer of pediatrics between the Transend group and the (historical) control group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of survey

Trials testing the same drug.

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04277286.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing